Caris Life Sciences, Inc. · Medical Laboratories

CAI

Low riskNext report: In 7 days (est.)

View price ↗

The short version

A company still losing money with growing sales.

Going well

Sales up 45% in the latest quarter vs a year ago
Sales up 97% last year

Watch out for

Losing money

Money moves

No insider buying or selling in the last 30 days
Institutions cut 1.8% from their holdings in the quarter ending June 2026 (173 bought, 71 sold)
Held by Philippe Laffont (Coatue), Stanley Druckenmiller (Duquesne)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$32.48+1.5% that day

Company value: $9.2B; Share price times all shares
Price vs profit (P/E): 19.2x; You pay about $19 for each $1 of yearly profit
Price vs sales: 9.3x; Company value is 9.3 times a year of sales
Cash vs value: 9%; Cash as a share of company value
Debt vs value: 4%; Debt as a share of company value

From CAI's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 9 quarters, from SEC filings

Sales, Jun '26

$263.7M+45% vs a year earlier

Jun '24Tap a barJun '26

Last 12 months: $989.6M, up 85% from the 12 months before.

What the price assumes

Your guesses, our math

Move the sliders to your own view of CAI. Starting points are the company's recent numbers.

Sales growth+30% a yearRecently: +85% a yearProfit margin11%Last 12 months: 10.6%P/E at the end19xToday: 19.2x. Many steady companies trade at 12x to 25xShare count change0% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$3.7B

Profit in 5 years$404M

Price these guesses point to$27.17-16% vs $32.48 todayAbout -3.5% a year, before dividends

What today's price needs: with a 11% margin and a 19x P/E, sales would have to grow about 35% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

1/3Weak

MissDebt under half of equityNot relying on borrowed money.0.66x equity
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.-8.4%
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$66.9M

Revenue: $812.0M; +97.0% vs prior year
Total debt: $378.4M; 0.66x equity
Current ratio: 7.85x; short-term assets / bills due
Free cash flow: $66.9M; 8.2% of revenue

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: return on equity 15%+, profitable every year, share count not growing, gross margin 40%+. A checklist is a starting point for research, not a verdict.